THERAVECTYS is a fully-integrated discovery and clinical development biotech company originating from Institut Pasteur and a pioneer in the development of lentiviral vector-based immunotherapy applications.
The company has optimized and industrialized next-generation methods to exploit the use of lentivectors in a variety of applications including therapeutic vaccines in infectious diseases and cancers as well as & CAR T-cells. Over time THERAVECTYS has built a broad and robust intellectual property position in addition to securing licenses to fundamental IP from Institut Pasteur and Institut Curie.
With the launch of the first-ever lentiviral vector vaccination trial and the recently demonstrated safety & immunogenicity human proof-of-concept of its core technology, the company is uniquely positionned to change the immunotherapy paradigm for the treatment of major global infectious diseases & cancers.
THERAVECTYS lead oncology vaccine candidate will enter the clinics in 2015, quickly followed by the company’s first CAR T-cell clinical trial program.
The company is based in Paris and currently employs 67 people.




Lentiviral vectors have the unique ability to transduce dividing cells – such as T-cells – and non-dividing cells – such as dendritic cells.
The transgene inserted into the lentiviral vector is under the regulation of a proprietary and patented human promoter (ß-2 microgobulin) overexpressed in APCs as well as in T-cells and NK cells.
Our vectors allow a performant transduction and a stable stimulation of dendritic cells, leading to MHC-class I & II mediated antigen presentation and inducing an intense, a broad and a durable CD4+ / CD8+ immune response.

Our improved & proprietary lentiviral vectors are:

  • integrative;
  • non-replicative;
  • non-pathogenic.

Our vectors incorporate single or multi-antigenic cassettes and can be used in prime & boost regimens.


With the aim to develop the most-efficient anti-cancer therapies, we are combining tumor-deprotection approaches with our improved lentiviral vector vaccines.

As a result, we have secured worldwide exclusive access to Institut Curie’s humanized synthetic nanobody library to:

  • screen & evaluate nanobodies to identify checkpoint inhibitors;
  • screen new tumor antigens;
  • and generate proprietary receptors for CAR and TCR-based therapies.

The synthetic nature of the library will allow the identification of nanobodies in less than six months as well as the engineering of their biochemical properties including affinity and stability.
Furthermore, the low molecular weight of nanobodies will allow their insertion into lentiviral vectors and will thus allow the expression of CARs on T-cells & NK-cells as well as offer the powerful combination of tumor de-protection with the intense, broad & long-lasting immune responses induced by the lentiviral vector vaccines.
With the addition of the nanobodies synthetic library from the Institut Curie, we own one of the most comprehensive immunotherapeutic platforms with the potential of a game-changer in the field of immuno-oncology.
With our broad & solid expertise in lentiviral vectors, we are uniquely positionned to fully leverage the technology in T-cells therapy applications (CARs & TCRs).
We are planning our entry in this highly attractive space with a fully-differentiated & integrated approach to overcome the current limitations of CAR T-cells therapies such as: safety post-reinfusion, long-term toxicity, efficacy against solid tumors, reactivation capability, treatment cost.



In January 2015, only 12 months after the initiation of the construction of our plant, we have been granted the status of a GMP pharmaceutical manufacturing establishment by the French National Agency for Medicines and Health Products Safety (ANSM).
The new facility is used to fulfill the company’s internal clinical development requirements in addition to those of strategic partners.
Theravectys2THERAVECTYS will produce in-house the lentiviral vectors to conduct its clinical trial Phase I/II in ATL/L (adult T leukemia/lymphoma induced by HTLV-1) as well as its differentiated CART-cell-based immunotherapy upcoming clinical trial.
With a total surface area of 750m2, including 340m2 multiple grade cleanrooms (A, B & C), the manufacturing facility integrates both production and quality control activities.
Run by an experienced GMP team, the plant is equiped with bioreactors (20L, 200L & up to 1’000L).

1 mail du Professeur Georges Mathé, 94800 VILLEJUIF, France
+33 01 43 90 19 20